Cong Zeng

Nov 6, 2024 | digitalcommons.library.tmc.edu | Panke Qu |John Evans |Chaitanya Kurhade |Cong Zeng

AbstractThe rapid spread and strong immune evasion of the SARS-CoV-2 Omicron subvariants has raised serious concerns for the global COVID-19 pandemic. These new variants exhibit generally reduced fusogenicity and increased endosomal entry pathway utilization compared to the ancestral D614G variant, the underlying mechanisms of which remain elusive. Here, we show that the C-terminal S1 mutations of the BA.1.1 subvariant, H655Y and T547K, critically govern the low fusogenicity of Omicron.

Feb 24, 2024 | dovepress.com | Shiyu Wang |Wei Qin |Tingting Cheng |Cong Zeng

IntroductionAllogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure hematologic malignancies through graft-versus-leukemia (GVL) effect to eliminate malignant cells. Regrettably, the efficacy of GVL is intertwined with the pathogenesis of graft-versus-host disease (GVHD).1 GVHD arises from donor T cells that, concurrently, orchestrate potent anti-tumor responses.